Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results
Continued Strong Growth with WAKIX® (pitolisant) Net Revenue of
Average Number of Patients on WAKIX Increased by ~350 Sequentially to ~5,800 for Third Quarter 2023
Remain Committed and Continue to Pursue Idiopathic Hypersomnia Indication; Next Step to Meet with FDA Informed by Review of Full Data Set
Expanded and Diversified Pipeline with Acquisition of Zynerba Pharmaceuticals; Zygel™ in Pivotal Phase 3 Trial for Fragile X syndrome
Repurchased ~1.4
Conference Call and Webcast to be Held Today at
“We continue to demonstrate very strong growth in our commercial business, with WAKIX in narcolepsy delivering the strongest revenue quarter in Harmony's history,” stated
“Given our continued confidence in the underlying strength of the business and our conviction in the growth potential for the company, we are announcing a new share repurchase program of
Third Quarter 2023 Financial Results
Net product revenues for the quarter ended
GAAP net income for the quarter ended
Reconciliations of applicable GAAP financial measures to Non-GAAP financial measures are included at the end of this press release.
Harmony’s operating expenses include the following:
- Research and Development expenses were
$17.5 million in the third quarter of 2023, as compared to$40.5 million for the same quarter in 2022, representing a 57% decrease, driven by a$30.0 million licensing fee as part of the 2022 LCA incurred during the third quarter of 2022; - Sales and Marketing expenses were
$23.4 million in the third quarter of 2023, as compared to$20.5 million for the same quarter in 2022, representing a 14% increase; - General and Administrative expenses were
$22.5 million in the third quarter of 2023, as compared to$21.3 million for the same quarter in 2022, representing a 6% increase; and - Total Operating Expenses were
$63.5 million in the third quarter of 2023, as compared to$82.3 million for the same quarter in 2022, representing a 23% decrease.
As of
Company Updates
- Reported topline results from the Phase 3 INTUNE study in adult patients with idiopathic hypersomnia (IH). While the primary endpoint did not reach statistical significance during the randomized withdrawal phase, a robust clinical effect was demonstrated in the open label phase of the study. Based on the totality of the data, the company remains committed and continues to pursue an indication for pitolisant in IH. Next step is to meet with the FDA informed by the review of the full data set.
- Received FDA alignment on the protocol for the Phase 3 TEMPO study in patients with Prader-Willi syndrome (PWS) which will satisfy the requirements for both the registrational trial and now pediatric exclusivity as well. We expect to initiate the study in the first quarter of 2024.
- On track for topline data from the Myotonic Dystrophy (DM1) Phase 2 proof-of-concept signal detection trial in the fourth quarter of 2023.
- On track to submit a supplemental new drug application (sNDA) for a pediatric narcolepsy indication to the FDA in the fourth quarter of 2023.
- Advancing new pitolisant based formulations into the clinic in the fourth quarter of 2023. Anticipate data in the first half of 2024.
- Expanded and diversified our pipeline with the acquisition of Zynerba Pharmaceuticals. Zygel is in a Pivotal Phase 3 trial for Fragile X syndrome (FXS).
- During the third quarter of 2023, the company repurchased 1,439,792 shares of common stock at an aggregate cost of
$50 million , as part of the prior$125 million share repurchase program, which we closed. - Our Board of Directors authorized a new
$200 million share repurchase program.
Conference Call Today at
We are hosting our third quarter 2023 financial results conference call and webcast today, beginning at
Non-GAAP Financial Measures
In addition to our GAAP results, we present certain Non-GAAP metrics including Non-GAAP adjusted net income and Non-GAAP adjusted net income per share, which we believe provides important supplemental information to management and investors regarding our performance. These measurements are not a substitute for GAAP measurements, and the manner in which we calculate Non-GAAP adjusted net income and Non-GAAP adjusted net income per share may not be identical to the manner in which other companies calculate adjusted net income and adjusted net income per share. We use these Non-GAAP measurements as an aid in monitoring our financial performance from quarter-to-quarter and year-to-year and for benchmarking against comparable companies.
Non-GAAP financial measures should not be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with our consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that we may exclude for purposes of our Non-GAAP financial measures; and we may in the future cease to exclude items that we have historically excluded for purposes of our Non-GAAP financial measures.
About WAKIX® (pitolisant) Tablets
WAKIX, a first-in-class medication, is approved by the
Indications and Usage
WAKIX is indicated for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy.
Important Safety Information
Contraindications
WAKIX is contraindicated in patients with known hypersensitivity to pitolisant or any component of the formulation. Anaphylaxis has been reported. WAKIX is also contraindicated in patients with severe hepatic impairment.
Warnings and Precautions
WAKIX prolongs the QT interval; avoid use of WAKIX in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval. Avoid use in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and the presence of congenital prolongation of the QT interval.
The risk of QT prolongation may be greater in patients with hepatic or renal impairment due to higher concentrations of pitolisant; monitor these patients for increased QTc. Dosage modification is recommended in patients with moderate hepatic impairment and moderate or severe renal impairment (see full prescribing information). WAKIX is not recommended in patients with end-stage renal disease (ESRD).
Adverse Reactions
In the placebo-controlled clinical trials conducted in patients with narcolepsy with or without cataplexy, the most common adverse reactions (≥5% and at least twice placebo) for WAKIX were insomnia (6%), nausea (6%), and anxiety (5%). Other adverse reactions that occurred at ≥2% and more frequently than in patients treated with placebo included headache, upper respiratory tract infection, musculoskeletal pain, heart rate increased, hallucinations, irritability, abdominal pain, sleep disturbance, decreased appetite, cataplexy, dry mouth, and rash.
Drug Interactions
Concomitant administration of WAKIX with strong CYP2D6 inhibitors increases pitolisant exposure by 2.2-fold. Reduce the dose of WAKIX by half.
Concomitant use of WAKIX with strong CYP3A4 inducers decreases exposure of pitolisant by 50%. Dosage adjustments may be required (see full prescribing information).
H1 receptor antagonists that cross the blood-brain barrier may reduce the effectiveness of WAKIX. Patients should avoid centrally acting H1 receptor antagonists.
WAKIX is a borderline/weak inducer of CYP3A4. Therefore, reduced effectiveness of sensitive CYP3A4 substrates may occur when used concomitantly with WAKIX. The effectiveness of hormonal contraceptives may be reduced when used with WAKIX and effectiveness may be reduced for 21 days after discontinuation of therapy.
Use in Specific Populations
WAKIX may reduce the effectiveness of hormonal contraceptives. Patients using hormonal contraception should be advised to use an alternative non-hormonal contraceptive method during treatment with WAKIX and for at least 21 days after discontinuing treatment.
There is a pregnancy exposure registry that monitors pregnancy outcomes in women who are exposed to WAKIX during pregnancy. Patients should be encouraged to enroll in the WAKIX pregnancy registry if they become pregnant. To enroll or obtain information from the registry, patients can call 1-800-833-7460. The safety and effectiveness of WAKIX have not been established in patients less than 18 years of age.
WAKIX is extensively metabolized by the liver. WAKIX is contraindicated in patients with severe hepatic impairment. Dosage adjustment is required in patients with moderate hepatic impairment.
WAKIX is not recommended in patients with end-stage renal disease. Dosage adjustment of WAKIX is recommended in patients with moderate or severe renal impairment.
Dosage reduction is recommended in patients known to be poor CYP2D6 metabolizers; these patients have higher concentrations of WAKIX than normal CYP2D6 metabolizers.
Please see the Full Prescribing Information for WAKIX for more information.
To report suspected adverse reactions, contact
About Narcolepsy
Narcolepsy is a rare, chronic, debilitating neurological disease of sleep-wake state instability that impacts approximately 165,000 Americans and is primarily characterized by excessive daytime sleepiness (EDS) and cataplexy – its two cardinal symptoms – along with other manifestations of REM sleep dysregulation (hallucinations and sleep paralysis), which intrude into wakefulness. EDS is the inability to stay awake and alert during the day and is the symptom that is present in all people living with narcolepsy. In most patients, narcolepsy is caused by the loss of hypocretin/orexin, a neuropeptide in the brain that supports sleep-wake state stability. This disease affects men and women equally, with typical symptom onset in adolescence or young adulthood; however, it can take up to a decade to be properly diagnosed.
About Idiopathic Hypersomnia
Idiopathic Hypersomnia (IH) is a rare and chronic neurological disease that is characterized by excessive daytime sleepiness (EDS) despite sufficient or even long sleep time. EDS in IH cannot be alleviated by naps, longer sleep or more efficient sleep. People living with IH experience significant EDS along with the symptoms of sleep inertia (prolonged difficulty waking up from sleep) and 'brain fog' (impaired cognition, attention, and alertness). The cause of IH is unknown, but it is likely due to alterations in areas of the brain that stabilize states of sleep and wakefulness. IH is one of the central disorders of hypersomnolence and, like narcolepsy, is a debilitating sleep disorder that can result in significant disruption in daily functioning.
About Prader-Willi Syndrome
PWS is an orphan/rare, genetic neurological disorder with many of the symptoms resulting from hypothalamic dysfunction. The hypothalamus is the part of the brain that controls both sleep-wake state stability and signals that mediate the balance between hunger and satiety, resulting in two of the main symptoms in patients with PWS; EDS and hyperphagia (an intense persistent sensation of hunger accompanied by food preoccupations, an extreme drive to consume food, food-related behavior problems, and a lack of normal satiety). Other features include low muscle tone, short stature, behavioral problems, and cognitive impairment. Approximately 15,000 to 20,000 people in the U.S. live with PWS, and over half of them experience EDS and the majority of them have behavioral disturbances.
About Zygel™
Zygel is the first and only pharmaceutically manufactured, synthetic cannabidiol, non-euphoric cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. Zygel is manufactured through a synthetic process in a cGMP facility and is not extracted from the cannabis plant. Therefore, it is devoid of THC, which is what causes the euphoric effect of cannabis, and has the potential to be a nonscheduled product if approved.
Cannabidiol, the active ingredient in Zygel, has been granted orphan drug designation by the FDA and the EMA for the treatment of FXS and for the treatment of 22q11.2 deletion syndrome (22q). Additionally, Zygel has received FDA Fast Track designation for the treatment of behavioral symptoms in patients with FXS.
About Fragile X Syndrome
Fragile X syndrome (FXS) is a rare genetic disorder that is the leading known cause of both inherited intellectual disability and autism spectrum disorder, affecting 1 in 3,600 to 4,000 males and 1 in 4,000 to 6,000 females. The disorder negatively affects synaptic function, plasticity and neuronal connections, and results in a spectrum of intellectual disabilities and behavioral symptoms, such as social avoidance and irritability. There are approximately 80,000 people in the
FXS is caused by a mutation in FMR1, a gene which modulates a number of systems, including the endocannabinoid system, and most critically, codes for a protein called FMRP. The FMR1 mutation manifests as multiple repeats of a DNA segment, known as the CGG triplet repeat, resulting in deficiency or lack of FMRP. FMRP helps regulate the production of other proteins and plays a role in the development of synapses, which are critical for relaying nerve impulses, and in regulating synaptic plasticity. In people with full mutation of the FMR1 gene, the CGG segment is repeated more than 200 times, and in most cases causes the gene to not function. Methylation of the FMR1 gene also plays a role in determining functionality of the gene. In approximately 60% of patients with FXS, who have complete methylation of the FMR1 gene, no FMRP is produced, resulting in dysregulation of the systems modulated by FMRP.
About
At
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our product WAKIX and our future capabilities following the acquisition of Zynerba. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our commercialization efforts and strategy for WAKIX; the rate and degree of market acceptance and clinical utility of WAKIX, pitolisant in additional indications, if approved, and any other product candidates we may develop or acquire, if approved; our research and development plans, including our development activities with
| HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARY CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (In thousands, except share and per share data) |
||||||||||||
| Three Months Ended |
Nine Months Ended |
|||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||
| Net product revenues | $ | 160,268 | $ | 117,206 | $ | 413,610 | $ | 309,547 | ||||
| Cost of product sold | 32,296 | 22,959 | 78,084 | 56,596 | ||||||||
| Gross profit | 127,972 | 94,247 | 335,526 | 252,951 | ||||||||
| Operating expenses: | ||||||||||||
| Research and development | 17,499 | 40,548 | 45,757 | 60,794 | ||||||||
| Sales and marketing | 23,418 | 20,467 | 70,518 | 58,210 | ||||||||
| General and administrative | 22,546 | 21,331 | 67,417 | 61,374 | ||||||||
| Total operating expenses | 63,463 | 82,346 | 183,692 | 180,378 | ||||||||
| Operating income | 64,509 | 11,901 | 151,834 | 72,573 | ||||||||
| Loss on debt extinguishment | (9,766) | — | (9,766) | — | ||||||||
| Other (expense) income, net | (5) | 56 | (34) | 96 | ||||||||
| Interest expense, net | (2,906) | (3,990) | (8,327) | (12,086) | ||||||||
| Income before income taxes | 51,832 | 7,967 | 133,707 | 60,583 | ||||||||
| Income tax (expense) benefit | (13,371) | 79,976 | (31,461) | 72,376 | ||||||||
| Net income | $ | 38,461 | $ | 87,943 | $ | 102,246 | $ | 132,959 | ||||
| Unrealized income (loss) on investments | 6 | (149) | (365) | (178) | ||||||||
| Comprehensive income | $ | 38,467 | $ | 87,794 | $ | 101,881 | $ | 132,781 | ||||
| EARNINGS PER SHARE: | ||||||||||||
| Basic | $ | 0.64 | $ | 1.48 | $ | 1.71 | $ | 2.25 | ||||
| Diluted | $ | 0.63 | $ | 1.44 | $ | 1.68 | $ | 2.18 | ||||
| Weighted average number of shares of common stock - basic | 59,863,102 | 59,234,720 | 59,856,941 | 59,070,063 | ||||||||
| Weighted average number of shares of common stock - diluted | 60,681,676 | 61,207,625 | 60,892,992 | 60,921,482 | ||||||||
CONSOLIDATED BALANCE SHEETS (In thousands except share and per share data) |
||||||||
| 2023 | 2022 | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash and cash equivalents | $ | 324,603 | $ | 243,784 | ||||
| Investments, short-term | 46,071 | 79,331 | ||||||
| Trade receivables, net | 67,264 | 54,740 | ||||||
| Inventory, net | 5,087 | 4,297 | ||||||
| Prepaid expenses | 14,269 | 9,347 | ||||||
| Other current assets | 5,704 | 8,786 | ||||||
| Total current assets | 462,998 | 400,285 | ||||||
| NONCURRENT ASSETS: | ||||||||
| Property and equipment, net | 428 | 573 | ||||||
| Restricted cash | 250 | 750 | ||||||
| Investments, long-term | 67,700 | 22,568 | ||||||
| Intangible assets, net | 143,069 | 160,953 | ||||||
| Deferred tax asset | 100,485 | 85,943 | ||||||
| Other noncurrent assets | 2,836 | 2,798 | ||||||
| Total noncurrent assets | 314,768 | 273,585 | ||||||
| TOTAL ASSETS | $ | 777,766 | $ | 673,870 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Trade payables | $ | 6,539 | $ | 3,786 | ||||
| Accrued compensation | 10,322 | 11,532 | ||||||
| Accrued expenses | 72,761 | 59,942 | ||||||
| Current portion of long-term debt | 15,000 | 2,000 | ||||||
| Other current liabilities | 7,786 | 1,624 | ||||||
| Total current liabilities | 112,408 | 78,884 | ||||||
| NONCURRENT LIABILITIES: | ||||||||
| Long-term debt, net | 182,131 | 189,647 | ||||||
| Other noncurrent liabilities | 1,895 | 2,501 | ||||||
| Total noncurrent liabilities | 184,026 | 192,148 | ||||||
| TOTAL LIABILITIES | 296,434 | 271,032 | ||||||
| COMMITMENTS AND CONTINGENCIES (Note 12) | ||||||||
| STOCKHOLDERS’ EQUITY: | ||||||||
| Common stock—$0.00001 par value; 500,000,000 shares authorized at |
1 | 1 | ||||||
| Additional paid in capital | 651,731 | 675,118 | ||||||
| Accumulated other comprehensive (loss) income | (516 | ) | (151 | ) | ||||
| Accumulated deficit | (169,884 | ) | (272,130 | ) | ||||
| TOTAL STOCKHOLDERS’ EQUITY | 481,332 | 402,838 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 777,766 | $ | 673,870 | ||||
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS (In thousands except share and per share data) |
||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| GAAP net income | $ | 38,461 | $ | 87,943 | $ | 102,246 | $ | 132,959 | ||||||||
| Non-GAAP Adjustments: | ||||||||||||||||
| Non-cash interest expense (1) | 2,221 | 418 | 3,061 | 1,241 | ||||||||||||
| Depreciation | 144 | 101 | 350 | 312 | ||||||||||||
| Amortization (2) | 5,962 | 5,962 | 17,884 | 17,005 | ||||||||||||
| Stock-based compensation expense | 7,957 | 6,967 | 22,311 | 19,234 | ||||||||||||
| Licensing fee (3) | - | 30,000 | - | 30,000 | ||||||||||||
| Loss on debt extinguishment | 9,766 | - | 9,766 | - | ||||||||||||
| Valuation allowance release | - | (74,474 | ) | - | (74,474 | ) | ||||||||||
| Income tax effect related to non-GAAP adjustments (4) | (5,723 | ) | 1,175 | (10,835 | ) | (2,341 | ) | |||||||||
| Non-GAAP adjusted net income | $ | 58,788 | $ | 58,092 | $ | 144,783 | $ | 123,936 | ||||||||
| GAAP reported net income per diluted share | $ | 0.63 | $ | 1.44 | $ | 1.68 | $ | 2.18 | ||||||||
| Non-GAAP adjusted net income per diluted share | $ | 0.97 | $ | 0.95 | $ | 2.38 | $ | 2.03 | ||||||||
| Weighted average number of shares of common stock used in non-GAAP diluted per share | 60,681,676 | 61,207,625 | 60,892,992 | 60,921,482 | ||||||||||||
(1) Includes amortization of deferred finance charges
(2) Includes amortization of intangible asset related to WAKIX
(3) Amount represents upfront licensing fee incurred upon closing the 2022 Licensing and Commercialization Agreement with
(4) Calculated using the reported effective tax rate for the periods presented less impact of discrete items
Harmony Biosciences Investor Contact:
445-235-8386
lsanay@harmonybiosciences.com
Harmony Biosciences Media Contact:
202-641-6086
cmccanless@harmonybiosciences.com
Source: Harmony Biosciences